Industry News

Aerie initiates phase 2b study of glaucoma drug

Aerie Pharmaceuticals has initiated a phase 2b study of a novel drug for the treatment of glaucoma, according to a press release.

PG324 is a fixed-combination of Aerie’s AR-13324 and latanoprost, the release said.

The study will be conducted on approximately 300 patients with glaucoma or ocular hypertension over the course of 28 days. Two concentrations of PG324 will be compared with latanoprost and AR-13324, separately, all dosed once daily. The primary outcome measure will be PG324’s efficacy compared with each of its components, in terms of decreases in mean diurnal IOP, according to the release.

Top-line results are expected in mid-2014.

Aerie Pharmaceuticals has initiated a phase 2b study of a novel drug for the treatment of glaucoma, according to a press release.

PG324 is a fixed-combination of Aerie’s AR-13324 and latanoprost, the release said.

The study will be conducted on approximately 300 patients with glaucoma or ocular hypertension over the course of 28 days. Two concentrations of PG324 will be compared with latanoprost and AR-13324, separately, all dosed once daily. The primary outcome measure will be PG324’s efficacy compared with each of its components, in terms of decreases in mean diurnal IOP, according to the release.

Top-line results are expected in mid-2014.